Table 3. Frequency of usage of different HRQoL tools in different publications.
| HRQoL tool | All publications | Phase I/II trial | Phase III trials | HRQoL indicator as primary end point |
HRQoL indicator as secondary end point |
Publications with liver directed therapies | Trials with liver-directed therapies | Studies with surgical interventions | Publications with systemic therapy | Trials with systemic therapy | Publications/trials |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Studies | Trials | Studies | Trials | Octreotide | Tamoxifen | Sorafenib | ||||||||||
| EORTC QLQ-C30 | 15 | 4 | 6 | 7 | 2 | 8 | 8 | 8 | 3 | 4 | 8 | 7 | 5 | 1 | 0 | |
| FACT-Hep | 14 | 5 | 2 | 8 | 2 | 6 | 4 | 6 | 2 | 4 | 5 | 4 | 2 | 0 | 1 | |
| FHSI-8 | 4 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 0 | 0 | 2 | |
| KPS | 3 | 2 | 1 | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 3 | 3 | 3 | 1 | 0 | |
| FACT-G | 3 | 2 | 0 | 2 | 1 | 1 | 1 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | |
| SF-36 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| POMS | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | |
| EORTC-QLQ-PAN | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | |
| QLQ- LC | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Euro QoL-VAS | 2 | 1 | 0 | 2 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| WHO-QoL-BREF | 2 | 1 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Patient data form | 2 | 2 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 2 | 2 | 0 | 0 | |
| Patient benefit form | 2 | 2 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 2 | 2 | 0 | 0 | |
| Spitzer QoL | 2 | 0 | 2 | 0 | 0 | 2 | 2 | 2 | 1 | 0 | 2 | 2 | 0 | 2 | 0 | |
| EORTC-QLQ-HCC18 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
| GQLI | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| SDS | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| HADS | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| FACIT-Sp-12 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
| Sexual history questionnaire | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| EuroQoL5D | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Standard gamble | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Global rating scale | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| SF-12 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Nottingham health profile | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 14 item questionnaire | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| 4 item questionnaire | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
GQLI, gastrointestinal quality of life index; SDS, symptom distress scale; HADS, hospital anxiety depression scale; HRQoL, health-related quality of life.